The reported data for compound screening with the bioluminescence resonance energy transfer (BRET 2 ) assay is very limited, and several questions remain unaddressed, such as the behavior of agonists. Eleven β2 adrenergic receptor (β2-AR) agonists were tested for full or partial agonism in an improved version of the receptor/β-arrestin2 BRET 2 assay and in 2 cyclic adenosine monophosphate (cAMP) assays (column cAMP assay and ALPHAscreen™ cAMP assay). Tested in the highly sensitive ALPHAscreen™ cAMP assay, all selected agonists behaved as full agonists, using isoproterenol as a reference compound. In the less sensitive column cAMP assay, ephedrine and dopamine had a clear partial response. For the BRET 2 assay, a highly graded picture was obtained. Moreover, β2-AR antagonists were tested for inverse agonism. Pronounced inverse agonism was detected in the ALPHAscreen™ cAMP assay. Only marginal inverse agonistic responses were seen for alprenolol and pindolol in the column cAMP assay, and no inverse agonism was seen in the BRET 2 assay. For the β2-AR, the BRET 2 assay may be superior for secondary screening of agonists where a separation of full and partial agonists is needed and the ALPHAscreen™ cAMP assay may be preferred for primary screening of agonists where all receptor activating compounds are desired. (Journal of Biomolecular Screening 2007:41-49) 
INTRODUCTION
T RADITIONALLY, binding and more recently functional cellbased assays for 7 trans membrane (7TM) receptors, also known as G protein-coupled receptors, have been used for compound screening. However, several distinct assays are currently needed to screen all 7TM receptors either by involving the natural signaling pathway or by the use of promiscuous G proteins. 1, 2 Alternatively, using the bioluminescence resonance energy transfer (BRET) assay measuring the receptor/β-arrestin interaction, one should in theory be able to screen practically all 7TM receptors. The BRET technology provides a reliable way to detect protein-protein interactions, and the interaction between 7TM receptors and β-arrestins has frequently been explored. [3] [4] [5] The apparently universal applicability of this assay relies on the fact that the receptor/β-arrestin interaction is common to virtually all 7TM receptors. 6, 7 Upon agonist stimulation, 7TM receptors initiate 2nd messenger signaling cascades through activated G protein subunits. Agonist stimulation also leads to rapid receptor phosphorylation by serine/threonine kinases known as G protein-coupled kinases (GRKs). The receptor, thus phosphorylated, has increased affinity for cytosolic proteins called β-arrestins. β-arrestin binding leads to the uncoupling of the receptor from its cognate G protein, causing dampening or desensitization of signaling via the downstream 2nd messenger molecules. 8 Moreover, β-arrestin also activates kinase-signaling pathways. 9, 10 Interaction between 7TM receptors and β-arrestins may be measured by means of standard bioluminescence principles. Using standard molecular biology techniques, Renilla luciferase (Rluc), being the donor molecule, may be fused to the receptor, and green fluorescent protein 2 (GFP 2 ), used as the acceptor molecule, may be fused to β-arrestin2. In the presence of a substrate for Rluc (e.g., DeepBlueC™), Rluc will emit light at a specific wavelength, and if the 2 proteins are in close proximity (<100 Å), resonance energy transfer (RET) will occur and light will be transferred from Rluc to GFP 2 . GFP 2 will then emit light at a distinct and different wavelength from Rluc. The BRET 2 signal is determined ratiometrically as the GFP 2 -light:Rluc-light ratio and expressed as miliBRET (BRET ratio × 1000).
7TM receptors may be divided into 2 classes with respect to the dynamics of the internalization process: class A receptors and class B receptors. 11 After β-arrestin recruitment to the receptor, a conformational change of β-arrestin will promote β-arrestin binding to adapter protein 2 (AP2) and clathrin, and the receptor/ β-arrestin complex is inserted into the clathrin-coated pit. This causes the receptor/β-arrestin complex to be internalized. If the receptor belongs to the class A receptors, the receptor/ β-arrestin complex rapidly dissociates following internalization, resulting in a short-lived and therefore weak BRET 2 signal. In the case of class B receptors, the receptor/β-arrestin complex stays together for a prolonged period of time, resulting in a high and sustained BRET 2 signal. β-arrestin mutants (7TM Pharma proprietary) have been created that will form more stable and longer lasting β-arrestin/receptor complexes, and in principle, all receptors will behave as class B receptors. 5 The preferred mutant prevents β-arrestin from binding to AP2 (β-Arr; R393E;R395E), thereby preventing internalization and subsequent dissociation of the receptor/arrestin complex. This results in a prolonged lifetime of the receptor/arrestin complex and therefore an enhanced BRET 2 signal. Cotransfection of these β-arrestin mutants with the neurokinin type 1 (NK1) receptor or the β2-receptor clearly has demonstrated the usefulness of these mutants for class A receptors and to a lesser degree for class B receptors. 5 Because of the technical intricacies associated with this technique, it is only recently that the BRET assay has been used as a screening assay. 12, 13 This is primarily because the luminescence readers, having necessary sensitivity may only now be equipped with online injectors. Therefore, the published data or empirical foundation for screening with the BRET 2 assay is very limited, and several questions remain unaddressed: The behavior of antagonists, inverse and partial agonists, the extension of constitutive activity, and the potential role and abundance of BRET pathwayspecific compounds are a few relevant examples. The behavior of antagonists has partly been addressed by the work of Vrecl and others, 5 in which antagonists of the NK1-R and β2 adrenergic receptor (β2-AR) were shown to produce the same level of antagonism in the traditional FLIPR ® calcium assay and the improved BRET 2 assay.
The present study was undertaken to examine the performance of known and well-characterized partial and inverse agonists in the BRET 2 assay and compare the activity of these agonists in the BRET 2 assay to the activity obtained in 2 different cAMP assays (column cAMP assay and ALPHAscreen™ cAMP assay).
It was decided to use the β2-AR as a model system as it is a well-characterized receptor for which numerous selective ligands, both agonist and antagonists, exist. The β2-AR acts via G s proteins and induces an increase in cAMP synthesis. 5, 14 The β2-AR represents the predominant subtype in most vascular and bronchial smooth muscle cells, and the β2-AR-mediated relaxation of smooth muscles plays an important physiological role in the regulation of vascular and bronchial tone. 15, 16 Indeed, a selection of clinically employed treatments of asthma target this receptor.
Moreover, since the β2-AR belongs to the class A receptor family, creating a relatively short-lived BRET 2 signal, it was decided to use the β-arrestin mutant, β-arr(R393E;R395E). HEK293 cells stably expressing GFP 2 /β-arr(R393E;R395E) cotransfected with β2-AR/Rluc have earlier been shown to provide Z′ values in the vicinity of 0.6 in the BRET assay. 5
MATERIALS AND METHODS

Rluc and GFP 2 fusion constructs
Human β-arrestin2 N-terminally tagged with GFP 2 (GFP 2 / β-arr2) construct was purchased from Perkin Elmer, Canada. The C-terminally tagged Rluc-receptor construct β2 adrenergic receptor/Rluc was made using standard molecular biology techniques. Mutation Arg 393,395 → Glu was introduced in human GFP 2 /β-arr2 using the QuickChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The use of this β-arr2 mutant requires a license from 7TM Pharma A/S. All cDNA clones were verified by sequencing.
Cell culture and transfection
A human embryonic kidney (HEK293) cell line stably expressing the Arg 393,395 → Glu β-arr2 mutant was established using standard cell culture techniques. The HEK293 cells were routinely maintained and passaged in minimum essential medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM Glutamax™-I, 1% nonessential amino acids, 1% sodium pyruvate, and 10 µg/ml gentamicin. The HEK293 cells were incubated at 37° C in a humidified atmosphere 5% (v/v) CO 2 in air. Transient transfection was performed in 70% confluent 175-cm 2 flasks using 7.5 µg β2-AR/Rluc DNA and Lipofectamine™. Using phosphate-buffered saline (PBS) containing ethylenediaminetetraacetate (5 mM), cells were harvested 48 h after transfection and then washed twice in PBS. The cell number was determined using a cover slip hemocytometer, and cells were resuspended in Dulbecco's PBS supplemented with 1 mg/l Dglucose to a density of 1 × 10 6 cells/ml for the BRET 2 assay or in stimulation buffer to a density of 1 × 10 6 cells/ml for the ALPHAscreen™ cAMP assay. Moreover, native African monkey green kidney (COS-7) cells were transfected with CXCR2/GFP 2 (20 µg) and Rluc/βarr (20 µg) or Vector (pcDNA3-1)/GFP 2 (20 µg) and Rluc/βarr (20 µg) using standard calcium-phosphate precipitation. The experiments including GRK, 7.5 µg of GRK 2, or GRK 5 cDNA were cotransfected with 7.5 µg of β2-AR/Rluc DNA using Lipofectamine™. All the tissue culture media and reagents were purchased from Gibco Invitrogen Corporation (Breda, the Netherlands), unless otherwise specified.
BRET 2 assay
The BRET 2 assay has previously been described. 5 Briefly, the assay was run using the Mithras LB 940 plate reader equipped with 4 injectors (Berthold Technologies, Bad Wildbad, Germany). Following harvesting in PBS (no IMBX added), 180 µl of resuspended cells containing ∼200,000 cells were distributed to wells in 96-well microplates (white Optiplate; PerkinElmer, Wellesley, MA) together with 10 µl agonist and incubated for 5 min. The plate was then transferred to the Mithras LB 940, where injector 1 injected 10 µl of the substrate DeepBlueC™ (final concentration 5 µM; PerkinElmer) to each well. Readings were collected 2 s after injections. The signals detected at 395 nm and 515 nm were measured sequentially, and the ratio of signal strength 515 nm:395 nm was calculated and expressed as a miliBRET level (BRET ratio × 1000).
cAMP column assay
One day after transfection, cells (1.5 × 10 5 cells/well) were incubated for 24 h with 2 µCi of [ 3 H]adenine (TRK 311; Amersham Pharmacia Biotech, Piscataway, NJ) in 0.5 ml of Dulbecco's 1885 medium supplemented with 10% fetal calf serum, 2 mM glutamine, and 0.01 mg/ml gentamicin in 24-well plates. Cells were washed twice and incubated for 15 min at 37 °C in 1 ml of freshly prepared binding buffer (HBS buffer: 25 mM HEPES, 0.75 mM Na 2 HPO 4 , 144 mM NaCl) supplemented with 1 mM isobutylmethylxanthine (IBMX; I5879, Sigma, St. Louis, MO), 40 µg/ml bacitracin, and the required concentration of agonist. After incubation, cells were placed on ice, the medium was removed, and cells were lysed with 1 ml of 5% (w/v) trichloroacetic acid, supplemented with 0.1 mM cAMP and 0.1 mM ATP for 30 min. The lysis mixtures were loaded onto a Dowex 50-X4 (142-1351; Bio-Rad, Hercules, CA) column (polyprep columns, 731-1550; Bio-Rad), which was washed with 2 ml water and placed on top of alumina columns (Sigma, A9003) and washed again with 10 ml of water. The columns were eluted with 6 ml of 0.1 M imidazole (Sigma, I0125) into 15 ml scintillation fluid (Highsafe III) followed by counting on Packard Tri-Carb scintillation counter o/n. Columns were reused up to 10 times. Dowex columns were regenerated by adding 10 ml of 2 N HCl followed by 10 ml of water; the alumina columns by adding 2 ml of 1 M imidazole, 10 ml of 0.1 M imidazole, and finally 5 ml of water.
ALPHAscreen™ ™ cAMP assay
The ALPHAscreen™ technology has thoroughly been described in the PerkinElmer ALPHAscreen™ cAMP assay kit manual. Briefly, the production of intracellular cAMP will generate a competition between unlabeled cAMP and exogenously added biotinylated cAMP for anti-cAMP antibodies conjugated to a bead (acceptor bead). A streptavidin-coated donor bead will recognize the biotinylated cAMP bead complex, forming a stable unit where the 2 beads are brought into close proximity. Upon laser excitation at 680 nm, a photosensitizer in the donor bead converts ambient triplet oxygen to the more excited singlet state. This step is responsible for very high signal amplification. If the beads are in close proximity, energy will be translocated to the acceptor bead, and a cascade of chemical reactions will finally lead to emission of fluorescent light at 520 to 620 nm. Assay conditions were changed slightly from the standard PerkinElmer procedure. All buffers were as per manufacturer instructions (including 0.5 mM IBMX final concentration). The assay was performed in 384-well microplates (OptiPlate-384; PerkinElmer). Fifteen microliters of cells (15,000 cells/well) were incubated with 10 µl of agonist for 60 min. Before addition of beads, the biotinylated cAMP (1 U/well) was preincubated with donor beads (1 U/well) for 30 min. Five microliters of acceptor beads (1 U/well) was added followed by 5 µl of the donor bead/ biotinylated cAMP suspension after 10 min of incubation. The plates were read on a Fusion plate reader after 3 h of incubation.
Before running the experiments presented in this article, a cAMP standard curve was performed. Moreover, forskolin dose-response curves were generated using different cell concentrations of the β2-AR transfected HEK293 GFP 2 /β-arr2 mutant clone. The forskolin dose-response curves obtained were related to the cAMP standard curve to establish the cell concentration providing a response, occupying most of the linear region of the cAMP standard curve with the highest signalto-background (S/B) ratio. With this experiment, we were confident that we would be within the linear range at all agonist concentrations tested because forskolin always gives the maximum S/B ratio.
Data analysis
For 96-well assays, columns 1 and 12 (or columns 1, 12, 13, and 24 for the 384-well plates) on each plate were dedicated for controls; to 8 wells was added a saturating concentration of isoproterenol (maximum response), and to a further 8 wells was added buffer (background). The average of each set of controls was used to define the top and bottom of a full agonist and was used to calculate the efficacy in percentage of each agonist concentration response curve tested. Moreover, an isoproterenol concentration response curve was tested on each assay plate. Each concentration response curve was tested in duplicate or in triplicate, and the average of each concentration point was normalized (100% to 0%) using the control values. Finally, the average ± SEM of the different concentrations for the individual agonist curves were calculated. With respect to the ALPHAscreen™, because it is a competition assay, the curves are descending with increasing concentrations, opposite to the 2 other assays. A transformation of the data was carried out to be able to display the curves with the same appearance.
RESULTS
Known full and partial β2-AR receptor agonists were tested in 3 different assays: the improved BRET 2 assay and 2 cAMP assays. The 1st cAMP assay was the traditional column chromatography methology cAMP assay, not well suited for screening purposes (e.g., very low throughput), and the ALPHAscreen™ cAMP assay (see the "Materials and Methods" section), which, by comparison, is much more sensitive and apt for drug screening. A stable GFP 2 /β-arrestin HEK293 cell line expressing the β-arr (R393E;R395E) mutant, which is independent of the AP2 pathway, was transfected with the fusion construct β2-AR/Rluc and used for all assays. Eleven β2 adrenergic agonists were tested; some of these are well-known asthma drugs such as salbutamol, salmeterol, and formoterol.
The ALPHAscreen™ assay reported full agonism for all compounds tested (Fig. 1A, 1B) , using the efficacy of isoproterenol as the set point for full agonism. This finding reflects a highly sensitive assay showing high coupling efficacy. Using the column assay, compounds such as ephedrine and dopamine clearly behaved as partial agonists (Fig. 1C, 1D) . Finally, the 11 β2 adrenergic agonists were tested in the BRET 2 assay, and a highly graded picture of the efficacies was seen ( Fig. 1E, 1F) , providing a higher level of information. Again, isoproterenol has been used as the reference compound. Epinephrine behaved as a full agonist, whereas norepinephrine, formoterol, and fenoterol displayed partial agonism. Ephedrine, dobutamine, dopamine, salometerol, salbutamol, and terbutaline gave no or close to no BRET 2 signal at all. This rank order of the compounds (i.e., epinephrine > isoproterenol > norepinephrine > dopamine) with respect to partial agonism has also been shown in both fluorescence spectroscopy and internalization studies. 17 Moreover, both formoterol and salmeterol are long-acting asthma drugs, and it has been shown in several different studies that salmeterol (and also salbutamol) has both a lower intrinsic activity and potency than formoterol. 18 Four β2 adrenergic antagonists were also tested in the 3 assays. The antagonists were tested in the absence of agonist. The ALPHAscreen™ assay revealed inverse agonism of alprenolol, pindolol, propranolol, and ICI 118551 ( Fig. 2A) . For comparison, the same degree of constitutive activity was observed testing the wild-type β2-AR in native HEK293 cells (data not shown). For the less-sensitive column cAMP assay, only a marginal but not significant inverse agonistic response was seen for propanolol and ICI 118551 ( Fig. 2B) . No constitutive activity, as measured by inverse agonism, was observed in the BRET 2 assay (Fig. 2C) .
However, the CXCR2 is an example of a receptor that constitutively recruits β-arrestin ( Fig. 3) as demonstrated by a statistically significant depression of basal activity for 2 CXCR2 inverse agonists (7TM Pharma proprietary compounds). Vector-transfected cells were also analyzed, and a clearly elevated basal response was seen for the receptor transfected cells (Fig. 3) . Only partial inverse agonism (50%-55%) was observed for the 2 compounds tested.
A stepwise decrease in potency for all compounds was seen when comparing the 3 assays: ALPHAscreen™ > column cAMP > BRET 2 ( Table 1) . Moreover, 6 compounds gave no or little response in the BRET 2 assay, and accordingly, the potency of these compounds was also found to be lower in the 2 cAMP assays. Only 1 compound, salmeterol, had no BRET 2 signal combined with relatively high potencies in the cAMP assays (Fig. 4) .The potencies of salmeterol resemble the potencies of isoproterenol in the 2 cAMP assays.
The BRET technology is closely related to the Norak Biosciences Transflour™ technology (Morrisville, NC), and it has been shown that isoproterenol has an EC 50 value of 5.3 nM using the Transflour™ technology compared to a slightly higher potency measured with the BRET assay (i.e., 69 nM). Moreover, saturation concentrations of isoproterenol, epinephrine, norepinephrine, and salbutamol revealed the same classification in the 2 assays, with the 2 former compounds being full agonists and the 2 latter compounds being partial agonists. 19 With respect to the potencies measured by the ALPHAscreen™ assay, it has been shown using another homogeneous screening-friendly cAMP assay, the FlashPlate assay (PerkinElmer), that isoproterenol, epinephrine, norepinephrine, and dopamine had similar EC 50 values as found applying the ALPHAscreen™ technology. 17 This study has only been focusing on screening for agonists, but it should be stressed that a different picture is obtained when screening for antagonists. In this setting, compounds show the same potency (or better) and efficacy in the BRET 2 assay compared to commonly used assays like FLIPR ® calcium and IP3 assays 5 (and unpublished data).
To further study the difference in the assay signal comparing the cAMP assay with the BRET 2 assay, the significance of agonist preincubation time and receptor phosphorylation was tested. Changing preincubation time with agonist from 5 to 30 min while performing the BRET 2 assay did not change the potency or the efficacy of salbutamol, salmeterol, and dopamine (data not shown). Because β-arrestin recruitment is dependent on receptor phosphorylation by GRKs, β2-AR/Rluc was cotransfected with GRK 2 or GRK 5 for potential optimization of receptor phosphorylation. Jorgensen et al. 20 have shown that this enhances the sensitivity of the BRET 2 assay. Moreover, McGraw and Liggett 21 demonstrated that a relatively low level of GRK 2 expression in human airway smooth muscle (HASM) is associated with an attenuated rate of short-term agonist-promoted β2-AR desensitization. This finding suggests that GRK 2 levels may be limited in agonist-specific β2-AR desensitization in HASM. A significant increase in efficacy was seen for 3 agonists tested after cotransfection with GRK 5 (Fig. 5) . A less-pronounced increase was seen with GRK 2 (data not shown). GRK 5 has previously been shown to be more effective than GRK 2 in both HEK293 and COS cells expressing the β2-AR. 22 Increasing the incubation time from 5 to 30 min with agonist of cells cotransfected with GRK 5 did not further increase the potency or efficacy of salbutamol, salmeterol, and dopamine (data not shown). To exclude artifacts using the β-arrestin mutant, we also tested isoproterenol, formoterol, salbutamol, and salmeterol against the wild-type β-arrestin in the BRET 2 assay. The overall picture was identical to that observed using the β-arrestin mutant although with a lower signal-to-noise ratio: Isoproterenol displayed full agonism, Eleven β2-AR agonists were tested using the stable HEK293-βarr2(R393E,R395E)/green fluorescent protein 2 cells transfected for 48 h with β2-AR/Renilla luciferase. Isoproterenol was used as a reference compound. Data shown are expressed as the percentage of the maximum response obtained with 1 µM of isoproterenol. Each dose-response curve represents data points (mean ± SEM) from at least 3 independent transfections. formoterol displayed partial agonism, and salbutamol and salmeterol gave no effect (data not shown). Finally, to make sure that there was no critical interference of endogenously expressed β2-ARs in the cAMP assays, vectortransfected cells were examined. The vector-transfected cells did not suggest the presence of endogenously expressed adrenergic receptors for any agonist tested using the column cAMP assay (data not shown). Only the very sensitive cAMP ALPHAscreen™ assay indicated endogenous expression of adrenergic receptors; however, isoproterenol had a 20-fold lower potency when tested on the mock-transfected cells compared to receptor-transfected cells, and no constitutive activity was detected. Since, alprenolol, propranolol, pindolol, and ICI 118551 did not act as inverse agonists (data not shown).
DISCUSSION
BRET has emerged as an extremely useful tool to study protein-protein interactions such as those involving 7TM receptors and β-arrestin proteins. The availability of new BRET detection systems suitable for high-throughput screening applications offers new opportunities to integrate the technology into the drug discovery process. However, the suitability of this assay for the screening of agonists has not been systematically examined. Clearly, both the apparent potency and efficacy of the 11 β2-AR agonists tested in this study differ in the 3 assays tested. A stepwise decrease in potency for all compounds was seen in viewing the 3 assays: ALPHAscreen™ > column cAMP > BRET 2 . Moreover, the cAMP assays revealed full or almost full agonism of all compounds tested, which reflects high sensitivity.
On the other hand, a highly graded picture of the efficacies was seen in the BRET 2 assay, revealing the high information content of this technique.
Only salmeterol differed from this general picture: inefficacious in BRET 2 but highly potent in the cAMP assays (see Table 1 and Fig. 4 ). There is no simple explanation for this; however, salmeterol differs from the rest of the β2-AR agonists tested by binding to the receptor exo-site and/or by partitioning into the membrane lipid, thereby extending the availability of agonist to the receptor. 23, 24 The prolonged presence of agonist at the receptor site correlates with numerous clinical studies indicating that the partial agonist salmeterol provides sustained bronchodilation and protection against exercise-induced asthma and nighttime exacerbation of asthma for at least 12 h following a single dose. 25 This does not explain why salmeterol did not promote a BRET 2 signal. It highlights that the lack of β-arrestin recruitment may prevent internalization of the receptors and thereby would potentially extend the action of the compound. But the sustained bronchodilatation is also seen for formoterol, which, on the other hand, acted as a partial agonist in the BRET 2 assay. Yet supporting the lack of β-arrestin recruitment, salmeterol confers reduced desensitization and EC 50 values were obtained from the dose-response curves displayed in Figure 1 . cAMP = cyclic adenosine monophosphate; BRET = bioluminescence resonance energy transfer; ND = no meaningful EC 50 values were obtained because of efficacies below 15% at the highest concentration tested. internalization as well as a reduced initial rate of phosphorylation of the β2-AR compared to adrenaline, which is a full agonist. 25 One may speculate that salmeterol may promote distinct differences in the cellular responses (i.e., activate cellular signaling events such as cAMP production and recruitment of β-arrestin to a different degree). The apparent potency and efficacy of agonists clearly is not solely dependent on an interaction between ligand and receptor but may be influenced by the entire environment of the cell (e.g., receptor expression level and phosphorylation capacity). Looking from outside the cell, the apparent sensitivity of the system may be increased by increasing the phosphorylation capacity from an apparently inadequate level, which increases the overall sensitivity of the assay. As mentioned before, it has been shown that the desensitization and internalization of β2-AR induced by the partial agonists salmeterol and salbutamol were considerably reduced relative to the action of adrenaline. Consistent with these observations, the initial rate of phosphorylation of the receptor induced by salmeterol and salbutamol was much reduced in comparison to adrenaline, 25 which is in accordance with the lack of any BRET 2 response to these 2 compounds. Moreover, Tran et al. 22 have shown correlation of initial levels of GRK site phosphorylation with the efficacy of activation of adenylate cyclase of a range of β2-AR agonists.
The degree of inverse agonism observed depends on the relative affinity of the inverse agonist for the various receptor species (conformations) and the degree of constitutive activity in the assay system (e.g., inherent assay sensitivity, receptor expression level). With respect to inverse agonism, the ALPHAscreen™ cAMP assay provides a more diverse readout than the 2 other assays, possibly because of the greatly amplified signal. One clearly observes that propranolol and ICI 118551 promote conformational changes leading to greater efficacies than for alprenolol and pindolol. A minor inverse agonistic effect, but not statistically significant, was also seen for propranolol and ICI 118551 in the column cAMP assay; however, no effect of the 4 compounds was seen in the BRET 2 assay. This contradicts the observations of Azzi et al., 4 who have demonstrated propranolol and ICI 118551 to be inverse agonists in the cAMP assay and to be agonists in the BRET 2 assay. In this context, it is worth mentioning that constitutive activity can be observed in the BRET assay (e.g., the CXCR2 is an example of a receptor that constitutively recruits β-arrestin).
The degree of partial and inverse agonism observed depends not only on the relative affinity of the compound for various receptor species (conformations), including signaling pathways and the capacity (i.e., phosphorylation capacity, receptor expression level) of the cell system, but also on the sensitivity of the applied assay. This means that differences in the coupling efficacy of receptor and G protein and differences in the capacity of receptor phosphorylation and internalization for different agonists may be eradicated by highly sensitive assays or fall prey to overinterpretation in assays of low sensitivity. In this study, factors such as receptor expression level and phosphorylation capacity are constant because the same cell system has been used for the 3 assays tested. Conversely, the sensitivity of agonists translated via the different signaling pathways and the 3 assay types vary significantly. Starting with the sensitivity of agonists for different signaling pathways, the BRET 2 assay performs a direct one-to-one measurement between receptor and β-arrestin, with no intermediate pathway molecules, as opposed to the cAMP assay, in which activation of one receptor induces activation of many G proteins as well as the production of many cAMP molecules, leading to greater downstream signal amplification. With respect to assay sensitivity, the ALPHAscreen™ technology provides a high concentration of photo sensitizer in each donor bead, which results in a very high signal amplification (see the "Materials and Methods" section). In comparison, there is no built-in signal amplification of the column cAMP assay. Finally, the sensitivity of the signal detection system also contributes to the final apparent potency and efficacy of agonists. The BRET 2 signal is measured on a Mithras plate reader (see the "Materials and Methods" section). The Mithras used for the present BRET 2 experiments is equipped with a cooled PMT (15° C). Increasing the sensitivity of the PMT by cooling below 0° C would possibly increase the sensitivity of the overall assay readout, and one could anticipate an assay outcome approaching the result seen applying the column cAMP assay. Taken as a whole, the outcome of a screen for agonists is influenced by multiple factors, and one may have to validate a particular assay and equipment with relevant reference compounds in each individual case; for example, the present data clearly show that increasing phosphorylation capacity by cotransfecting with GRK 5 significantly changes the outcome of tested agonists. In this context, one should also take into account that every cell has its own inherent amplification factor, and so it is nearly certain that the pharmacological test system in which activity is optimized will differ more or less from the therapeutically relevant cell.
In conclusion, it is not a trivial matter to pick the right agonist screening assay because the outcome of an agonist screen is closely linked to the environment of the cell and the sensitivity of the assay. However, learning about the behavior of wellcharacterized agonists in different assays and cellular environments will give valuable information for the extrapolation of in vitro data to the in vivo situation. An excellent example is salmeterol, which in several studies has been shown to be a partial agonist compared to formoterol. 18 This information clearly does not surface in the cAMP assay but only in the BRET assay. However, the sensitivity offered by the ALPHAscreen™ cAMP assay would be the preferred level in a primary screening for agonists, in which all compounds interacting with the receptor would be of interest. But one should keep in mind that if receptor coupling is less efficient in vivo, then partial agonism, or even antagonism, could be observed. Normally, compounds are progressed from primary screening assays into therapeutically oriented secondary assays. The lower sensitivity of the present β2-AR BRET 2 assay would be suitable for secondary screening of agonists. As shown in this study, one obtains a grading of the efficacy of the tested compounds. Hence, information in both assays (BRET and cAMP assays) is not redundant but rather complementary and creates a form of high-content screening. The opportunity to test compounds in assays focusing on different cellular signaling pathways (e.g., ALPHAscreen™ cAMP assay and BRET 2 assay) also opens the possibility of obtaining a more complex and information-rich picture of the impact a drug may have on a cell, which may lead to a better understanding of the differences seen for related compounds. Finally, defining these parameters will aid in a better understanding of the mode of action for drugs in various diseases.
